252 related articles for article (PubMed ID: 30611847)
21. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
22. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
23. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
24. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
Thangapandian S; John S; Lee Y; Kim S; Lee KW
Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
[TBL] [Abstract][Full Text] [Related]
25. Inhibition and mechanism of HDAC8 revisited.
Chen K; Zhang X; Wu YD; Wiest O
J Am Chem Soc; 2014 Aug; 136(33):11636-43. PubMed ID: 25060069
[TBL] [Abstract][Full Text] [Related]
26. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
27. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
Ortore G; Di Colo F; Martinelli A
J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
29. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
30. Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors.
He B; Velaparthi S; Pieffet G; Pennington C; Mahesh A; Holzle DL; Brunsteiner M; van Breemen R; Blond SY; Petukhov PA
J Med Chem; 2009 Nov; 52(22):7003-13. PubMed ID: 19886628
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
32. Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8.
Porter NJ; Christianson DW
ACS Chem Biol; 2017 Sep; 12(9):2281-2286. PubMed ID: 28846375
[TBL] [Abstract][Full Text] [Related]
33. Electrophilic MiniFrags Revealed Unprecedented Binding Sites for Covalent HDAC8 Inhibitors.
Keeley AB; Kopranovic A; Di Lorenzo V; Ábrányi-Balogh P; Jänsch N; Lai LN; Petri L; Orgován Z; Pölöske D; Orlova A; Németh AG; Desczyk C; Imre T; Bajusz D; Moriggl R; Meyer-Almes FJ; Keserü GM
J Med Chem; 2024 Jan; 67(1):572-585. PubMed ID: 38113354
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study.
Yao P; Gao Q; Wang Y; Yao Q; Zhang J
ChemMedChem; 2021 Jun; 16(12):1933-1944. PubMed ID: 33686739
[TBL] [Abstract][Full Text] [Related]
35. Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Zhang M; Ying JB; Wang SS; He D; Zhu H; Zhang C; Tang L; Lin R; Zhang Y
J Cell Biochem; 2020 Jun; 121(5-6):3162-3172. PubMed ID: 31907955
[TBL] [Abstract][Full Text] [Related]
36. The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
Jänsch N; Meyners C; Muth M; Kopranovic A; Witt O; Oehme I; Meyer-Almes FJ
Redox Biol; 2019 Jan; 20():60-67. PubMed ID: 30292946
[TBL] [Abstract][Full Text] [Related]
37. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
[TBL] [Abstract][Full Text] [Related]
38. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
40. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
